Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sagimet Biosciences's quarterly cash, cash equivalents, marketable securities
declined
from Dec. 2025 (€96.61 Mil) to Mar. 2026 (€90.43 Mil) but then
increased
from Mar. 2026 (€90.43 Mil) to Jun. 2026 (€208.43 Mil).
Sagimet Biosciences's annual cash, cash equivalents, marketable securities
increased
from Dec. 2023 (€87.02 Mil) to Dec. 2024 (€144.44 Mil) but then
declined
from Dec. 2024 (€144.44 Mil) to Dec. 2025 (€96.61 Mil).
Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.
A high number means either:
1) The company has competitive advantage generating lots of cash
2) Just sold a business or bonds (not necessarily good)
A low stockpile of cash usually means poor to mediocre economics.
There are 3 ways to create large cash reserve.
1) Sell new bonds or equity to public
2) Sell business or asset
3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)
When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.
Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.
Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.
Sagimet Biosciences Cash, Cash Equivalents, Marketable Securities Related Terms
Sagimet Biosciences Cash, Cash Equivalents, Marketable Securities Historical Data
* Premium members only.
The historical data trend for Sagimet Biosciences's Cash, Cash Equivalents, Marketable Securities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.
What does a Cash, Cash Equivalents, Marketable Securities of €208.43 Mil mean?
Sagimet Biosciences (STU:0O2) has a Cash, Cash Equivalents, Marketable Securities of €208.43 Mil as of Jun. 2026. The total cash, cash equivalents and marketable securities a company has on hand. View historical data on Sagimet Biosciences and its competitors.
Is Sagimet Biosciences' Cash, Cash Equivalents, Marketable Securities too high?
Sagimet Biosciences' current Cash, Cash Equivalents, Marketable Securities is €208.43 Mil. Overall, Sagimet Biosciences has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' Cash, Cash Equivalents, Marketable Securities compare to CABA and OVID?
Sagimet Biosciences' Cash, Cash Equivalents, Marketable Securities of €208.43 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash, Cash Equivalents, Marketable Securities for a Biotechnology company?
A good Cash, Cash Equivalents, Marketable Securities depends on the Biotechnology industry context. However, Cash, Cash Equivalents, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash, Cash Equivalents, Marketable Securities mean?
A high Cash, Cash Equivalents, Marketable Securities can signal that a stock is expensive relative to its fundamentals. The total cash, cash equivalents and marketable securities a company has on hand. View historical data on Sagimet Biosciences and its competitors. Sagimet Biosciences's current Cash, Cash Equivalents, Marketable Securities is €208.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Sagimet Biosciences (STU:0O2) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.69, compared to a current price of €8.74 — trading 53.6% above its estimated fair value. The current Cash, Cash Equivalents, Marketable Securities is €208.43 Mil. Sagimet Biosciences' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash, Cash Equivalents, Marketable Securities calculated?
Cash, Cash Equivalents, Marketable Securities is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Cash, Cash Equivalents, Marketable Securities is €208.43 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sagimet Biosciences (STU:0O2) Overvalued in 2026?
Based on GuruFocus' analysis, Sagimet Biosciences stock appears to be overvalued.
The current stock price of €8.74 is trading 53.6% above its estimated GF Value™ of €5.69.
GuruFocus considers Sagimet Biosciences to be Significantly Overvalued.
Key valuation signals for STU:0O2:
Cash, Cash Equivalents, Marketable Securities: €208.43 Mil
GF Value™: €5.69 vs. price of €8.74 (53.6% above fair value)
No single metric tells the full story. See the STU:0O2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
33GF Score
Get the complete analysis for STU:0O2
Cash, Cash Equivalents, Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0O2 has been successfully added to your 
